Decision-making at the surface of the intact or barrier disrupted skin: Potential applications for vaccination or therapy

Cellular and Molecular Life Sciences

Volumn 62, Issue 13, 2005, Pages 1418-1424

  Partidos, C D ^a   Muller, S ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Adjuvant; Autoimmunity; Enterotoxin; Skin barrier; Skin immunity; Vaccine

Indexed keywords

ADJUVANT; ALLERGEN; BACTERIAL DNA; CHEMOKINE; CYTOKINE; EXOTOXIN; GAMMA INTERFERON; GROWTH FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN E ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OLIGODEOXYNUCLEOTIDE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 5; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CYTOKINE RELEASE; DECISION MAKING; DELAYED HYPERSENSITIVITY; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HYPERSENSITIVITY REACTION; IMMUNIZATION; IMMUNOLOGY; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; MICROENVIRONMENT; MULTIPLE SCLEROSIS; NONHUMAN; PARALYSIS; REVIEW; SKIN; SKIN EPITHELIUM; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIGENS; CHOLERA TOXIN; EPIDERMIS; HUMANS; IMMUNITY, CELLULAR; KERATINOCYTES; LANGERHANS CELLS; SKIN; VACCINATION; VACCINES;

EID: 21544455238     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-005-4529-1     Document Type: Review

References (56)

1. Streilein J. W. (1983) Skin-associated lymphoid tissues (SALT): origins and functions. J. Invest. Dermatol. 80: 12s-16s
2. Stingl G. (1993) The skin: initiation and target site of immune responses. Recent Results Cancer Res. 128: 45-57
3. Nestle F. O., Filgueira L., Nickoloff B. J. and Burg G. (1998) Human dermal dendritic cells process and present soluble protein antigens. J. Invest. Dermatol. 110: 762-766
4. Williams I. R. and Kupper T. S. (1996) Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci. 58: 1485-1507
5. Uchi H., Terao H., Koga T. and Furue M. (2000) Cytokines and chemokines in the epidermis. J. Dermatol. Sci. 24: S29-S38
6. Steinhoff M., Brzoska T. and Luger T. A. (2001) Keratinocytes in epidermal immune responses. Curr. Opin. Allergy Clin. Immunol. 1: 469-476
7. Ali R. S., Falconer A., Ikram M., Bissett C. E., Cerio R. and Quinn A. G. (2001) Expression of the peptide antibiotics human beta defensin-1 and human beta defensin-2 in normal human skin. J. Invest. Dermatol. 117: 106-111
8. Grone A. (2002) Keratinocytes and cytokines. Vet. Immunol. Immunopathol. 88: 1-12
9. Iwasaki A. and Medzhitov R. (2004) Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995
10. Baker B. S., Ovigne J. M., Powles A. V., Corcoran S. and Fry L. (2003) Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br. J. Dermatol. 148: 670-679
11. Pivarcsi A., Bodai L., Rethi B., Kenderessy-Szabo A., Koreck A., Szell M. et al. (2003) Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int. Immunol. 15: 721-730
12. Wolff K. and Honigsmann H. (1971) Permeability of the epidermis and the phagocytic activity of keratinocytes: ultrastructural studies with thorotrast as a marker. J. Ultrastruct. Res. 36: 176-190
13. Nickoloff B. J., Mitra R. S., Green J., Zheng X. G., Shimizu Y., Thompson C. et al. (1993) Accessory cell function of keratinocytes for superantigens: dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J. Immunol. 150: 2148-2159
14. Debenedictis C., Ioubeh S., Zhang G., Barria M. and Ghohestani R. F. (2001) Immune functions of the skin. Clin. Dermatol. 19: 573-585
15. Cumberbatch M., Dearman R. J., Griffiths C. E. and Kimber I. (2000) Langerhans cell migration. Clin. Exp. Dermatol. 25: 413-418
16. Jakob T., Ring J. and Udey M. C. (2001) Multistep navigation of Langerhans/dendritic cells in and out of the skin. J. Allergy Clin. Immunol. 108: 688-696
17. Belyakov I. M. and Berzofsky J. A. (2004) Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity. 20: 247-253
18. Belyakov I. M., Hammond S. A., Ahlers J. D., Glenn G. M. and Berzofsky J. A. (2004) Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113: 998-1007
19. Paul A., Cevc G. and Bachhawat B. K. (1998) Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine 16: 188-195
20. Glenn G. M., Rao M., Matyas G. R. and Alving C. R. (1998) Skin immunization made possible by cholera toxin. Nature 391: 851
21. Partidos C. D. (2003) Delivering vaccines into the skin without needles and syringes. Expert Rev. Vaccines 2: 753-761
22. Wood L. C., Jackson S. M., Elias P. M., Grunfeld C. and Feingold K. R. (1992) Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J. Clin. Invest. 90: 482-487
23. Cumberbatch M., Dearman R. J. and Kimber I. (1997) Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology 92: 388-395
24. Schwarzenberger K. and Udey M. C. (1996) Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ. J. Invest. Dermatol. 106: 553-558
25. Price A. A., Cumberbatch M., Kimber I. and Ager A. (1997) Alpha 6 integrins are required for Langerhans cell migration from the epidermis. J. Exp. Med. 186: 1725-1735
26. Sozzani S., Allavena P., D'Amico G., Luini W., Bianchi G., Kataura M. et al. (1998) Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. 161: 1083-1086
27. Wang X. P., Schunck M., Kallen K. J., Neumann C., Trautwein C., Rose-John S. et al. (2004) The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J. Invest. Dermatol. 123: 124-131
28. Dorschner R. A., Pestonjamasp V. K., Tamakuwala S., Ohtake T., Rudisill J., Nizet V. et al. (2001) Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 117: 91-97
29. Tani K., Murphy W. J., Chertov O., Salcedo R., Koh C. Y., Utsunomiya I. et al. (2000) Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. 12: 691-700
30. Biragyn A., Ruffini P. A., Leifer C. A., Klyushnenkova E., Shakhov A., Chertov O. et al. (2002) Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298: 1025-1029
31. Watford W. T., Moriguchi M., Morinobu A. and O'Shea J. J. (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 14: 361-368
32. Mosmann T. R. (1994) Properties and functions of interleukin-10. Adv. Immunol. 56: 1-26
33. Nickoloff B. J. and Naidu Y. (1994) Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30: 535-546
34. Kondo H., Ichikawa Y. and Imokawa G. (1998) Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur. J. Immunol. 28: 769-779
35. Schmuth M., Neyer S., Rainer C., Grassegger A., Fritsch P., Romani N. et al. (2002) Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp. Dermatol. 11: 135-142
36. Dieu-Nosjean M. C., Massacrier C., Homey B., Vanbervliet B., Pin J. J., Vicari A. et al. (2000) Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J. Exp. Med. 192: 705-718
37. Kahlon R., Hu Y., Orteu C. H., Kifayet A., Trudeau J. D., Tan R. et al. (2003) Optimization of epicutaneous immunization for the induction of CTL. Vaccine 21: 2890-2899
38. Glenn G. M., Kenney R. T., Ellingsworth L. R., Frech S. A., Hammond S. A. and Zoeteweij J. P. (2003) Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2: 253-267
39. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F. and Takigawa M. (2000) Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad. Sci. USA 97: 371-376
40. Riminton D. S., Kandasamy R., Dravec D., Basten A. and Baxter A. G. (2004) Dermal enhancement: bacterial products on intact skin induce and augment organ-specific autoimmune disease. J. Immunol. 172: 302-309
41. Su S. B., Silver P. B., Wang P., Chan C. C. and Caspi R. R. (2004) Cholera toxin prevents Th1-mediated autoimmune disease by inducing immune deviation. J. Immunol. 173: 755-761
42. Szczepanik M. (2002) Skin induced tolerance and its clinical implications. Mod. Asp. Immunobiol. 2: 265-268
43. Bynoe M. S., Evans J. T., Viret C. and Janeway C. A. Jr (2003) Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 19: 317-328
44. Wang L. F., Lin J. Y., Hsieh K. H. and Lin R. H. (1996) Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice. J. Immunol. 156: 4077-4082
45. Wang L. F., Sun C.-C., Wu J.-T. and Lin R.-H. (1998) Epicutaneous administration of hapten through patch application augments TH2 responses which can downregulate the elicitation of murine contact hypersensitivity. Clin. Exp. Allergy 29: 271-279
46. Strid J., Hourihane J., Kimber I., Callard R. and Strobel S. (2004) Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur. J. Immunol. 34: 2100-2109
47. Herrick C. A., MacLeod H., Glusac E., Tigelaar R. E. and Bottomly K. (2000) Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J. Clin. Invest. 105: 765-775
48. Anjuere F., George-Chandy A., Audant F., Rousseau D., Holmgren J. and Czerkinsky C. (2003) Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J. Immunol. 170: 1586-1592
49. Spangler B. D. (1992) Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56: 622-647
50. Sun J. B., Holmgren J. and Czerkinsky C. (1994) Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 91: 10795-10799
51. Krieg A. M. (2003) CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9: 831-835
52. Klinman D. M., Currie D., Gursel I. and Verthelyi D. (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199: 201-216
53. Klinman D. M. (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4: 249-258
54. Beignon A. S., Briand J. P., Muller S. and Partidos C. D. (2002) Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 105: 204-212
55. Partidos C. D., Beignon A. S., Briand J. P. and Muller S. (2004) Modulation of immune responses with transcutaneously deliverable adjuvants. Vaccine 22: 2385-2390
56. Zare F., Bokarewa M., Nenonen N., Bergstrom T., Alexopoulou L., Flavell R. A. et al. (2004) Arthritogenic properties of double-stranded (viral) RNA. J. Immunol. 172: 5656-5663